| Outcome Measures: |
Primary: Change in HbA1c, from baseline to week 24 | Secondary: Percentage of patients with HbA1c < 7%, at week 24|Percentage of patients with HbA1c < 6.5%, at week 24|Change in Fasting Plasma Glucose (FPG), from baseline to week 24|Number of patients with adverse events, over the 24-week treatment period|Hypoglycemia, over the 24-week treatment period
|
| Locations: |
Investigational Site Number 422-002, Beirut, Lebanon|Investigational Site Number 422-001, Hazmieh, Lebanon|Investigational Site Number 643001, Samara, Russian Federation|Investigational Site Number 643002, St-Petersburg, Russian Federation|Investigational Site Number 643-03, St.-Petersburg, Russian Federation|Investigational Site Number 804003, Chernivtsi, 58022, Ukraine|Investigational Site Number 804008, Donetsk, 83003, Ukraine|Investigational Site Number 804004, Donetsk, 83059, Ukraine|Investigational Site Number 804001, Donetsk, 83099, Ukraine|Investigational Site Number 804010, Odessa, Ukraine|Investigational Site Number 804006, Poltava, 36011, Ukraine|Investigational Site Number 804007, Vinnytsya, 21010, Ukraine|Investigational Site Number 804002, Vinnytsya, 21029, Ukraine
|